David W. Goodman, MD

Johns Hopkins Medical Institutions, Department of Psychiatry, Baltimore, Maryland; Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York

  • 9Articles
  • 109.7KReads
  • 2008–2026Active
  • 51Collaborators
  • 358Citations

About

David W. Goodman, MD, affiliated with Johns Hopkins Medical Institutions and SUNY Upstate Medical University, has published extensively on neurodevelopmental and psychiatric disorders, focusing particularly on adult Attention-Deficit/Hyperactivity Disorder (ADHD). His work encompasses clinical studies on ADHD diagnosis, management, and treatment, including pharmacological interventions such as osmotic-release oral system methylphenidate and lisdexamfetamine dimesylate. Additionally, he has explored topics related to anxiety, depression, psychopharmacology, and the differentiation of physical symptoms following antidepressant cessation.

Publications

JCP
When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?
ASCP Corner

When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?

August 6, 2026

Focuses on descriptive symptom phenomenology and strategies to minimize discomfort during antidepressant cessation, with possible explanations for unusual, delayed, or protracted symptoms in patients for whom non-pharmacodynamic features may...
, , , et al
PCC
Burden of ADHD in Adults
Original Research

Burden of ADHD in Adults

March 14, 2023

The effect of mental health comorbidities should be considered in the overall management of adults with ADHD.
, , , et al
JCP
Original Research

Methylphenidate Dosage for ADD/ADHD

January 25, 2017

Read a placebo-controlled study discussing OROS methylphenidate dosages in treatment for Adult Attention-Deficit/Hyperactivity Disorder (ADHD).
, , , et al
PCC
Article

Adult ADHD in the DSM-5 Era

November 17, 2016

The recent update on ADHD diagnostic criteria in the DSM-5 may increase the diagnosis of ADHD in adults. Thus, it is important to raise awareness and improve knowledge of...
,
PCC
Article

Assessment of Physician Practices in Adult Attention-Deficit/Hyperactivity Disorder

August 2, 2012

Adult attention-deficit/hyperactivity disorder (ADHD) is a common neuropsychiatric disorder, yet only 1 in 10 affected adults receives treatment. The study objective was to assess gaps in knowledge and describe...
, , , et al
JCP
Original Research

Lifespan Persistence of ADHD: The Life Transition Model and Its Application

January 10, 2012

, , , et al
JCP
Original Research

Moderators and Mediators of Symptoms and Quality of Life Outcomes in an Open-Label Study of Adults Treated for Attention-Deficit/Hyperactivity Disorder

February 23, 2010

, , , et al
JCP
Original Research

Short-Term Effects of Lisdexamfetamine Dimesylate on Cardiovascular Parameters in a 4-Week Clinical Trial in Adults With Attention-Deficit/Hyperactivity Disorder

December 15, 2009

, , , et al
JCP
Original Research

Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder

September 30, 2008

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe